Abstract: The compounds of the subject invention are related to 2-substituted cephem compounds, which have a wide antimicrobial spectrum, in particular exhibit potent antimicrobial activity against beta-lactamase producing Gram negative bacteria, and pharmaceutical compositions comprising the same.

Abstract: Compounds of formula (I) wherein; R1 is hydrogen or C1-6alkyl; R2 is hydrogen, C1-6alkyl, perhalomethylC0-5alkyl-O—, or C1-6alkoxy; R3 is hydrogen, C1-6alkyl, or C1-6alkoxyC1-6alkyl; R4 is hydrogen, C1-6alkyl, perhalomethylC1-6alkyl; or unsubstituted C3-6cycloalkylC1-6alkyl; A is C—R5 or N; B is C—R6 or N; D is C—R7 or N; with the proviso that at least one of A, B, and D, is N; R5 is hydrogen or C1-6alkyl; R6 is hydrogen or C1-6alkyl; R7 is hydrogen, C1-6alkyl, C1-6alkoxy, or hydroxy; R8 is hydrogen or C1-6alkyl, with the proviso that one of R4 and R8 is hydrogen; R9 is hydrogen or hydroxy; R10 is hydrogen or C1-6alkyl; and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.

Abstract: A method of treating vitiligo, including prophylaxis, in a subject in need thereof, comprising administering to said subject a pharmaceutically effective amount of a compound of Formula (I): wherein: X is CR1 or N; Y is CH, C or N; R1 is hydrogen, C1-6alkoxy or C1-6alkyl; R2 is hydrogen, C1-6alkoxy, halo, —C(O)C1-6alkyl, CN, halo-C1-6alkyl or —C(O)NR4R5; R3 is hydrogen or C1-6alkoxy; R4 is hydrogen or C1-6alkyl: R5 is hydrogen or C1-6alkyl; and m and n are integers each independently selected from 1 and 2, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to novel retinoid-related orphan receptor gamma (ROR?) modulators and their use in the treatment of diseases mediated by ROR?.

Abstract: A dispenser for the delivery of a droplet of a liquid comprises a housing which defines an outlet orifice, a tip seal, biased against the housing to seal the outlet orifice, and a dosing pump for pumping a liquid to the outlet nozzle. The dispenser further comprises an actuation pump configured to provide a hydraulic opening force to the tip seal for opening of the outlet orifice. Preferably the actuation pump is configured to operate at a higher pressure than the dosing pump.

Abstract: An assembly having: a container configured to contain a product, the container having an end having a dispensing end surface, a central axis which extends through the end, and a neck underneath the end, the neck having an outer surface which tapers outwardly away from the central axis as it extends in a direction towards the end; an accessory non-removably mounted on the end of the container, the accessory having a surface bearing against the dispensing end surface of the container, and a sleeve disposed about the neck so that an inner surface of the sleeve is in facing relation with the neck outer surface, and; an annular collar wedged between the sleeve inner surface and the neck outer surface and joined to the sleeve inner surface by a permanent joint.

Abstract: The disclosure provides an anti-TGFbetaRII immunoglobulin single variable domain. Suitably, an anti-TGFbetaRII immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of SEQ ID NO:1-28 having up to 5 amino acid substitutions, deletions or additions. The disclosure further provides a polypeptide and pharmaceutical composition for treating a disease associated with TGFbeta signalling and suitably a disease selected from the group of: tissue fibrosis, such as pulmonary fibrosis, including idiopathic pulmonary fibrosis; liver fibrosis, including cirrhosis and chronic hepatitis; rheumatoid arthritis; ocular disorders; fibrosis of the skin, including keloid of skin; Dupuytren's Contracture; kidney fibrosis such as nephritis and nephrosclerosis; wound healing; scarring reduction; and a vascular condition, such as restenosis.

Abstract: An oral care composition which is a liquid at or below room temperature and which forms a two-phase cloudy system at body temperature and wherein the composition comprises a water-soluble non-ionic polymer, such as HPC, having a cloud point in the composition at a temperature no higher than about 38° C., for combating (i.e. helping to prevent, inhibit and/or treat) dentinal hypersensitivity.

Abstract: Compounds of formula (I): wherein; R1 is hydrogen or C1-6alkyl; R2 is hydrogen, C1-6alkyl, perhalomethylC0-5alkyl-O—, or C1-6alkoxy; R3 is hydrogen, C1-6alkyl, or C1-6alkoxyC1-6alkyl; R4 is hydrogen, C1-6alkyl, perhalomethylC1-6alkyl; or unsubstituted C3-6cycloalkylC1-6alkyl; A is C—R5 or N; B is C—R6 or N; D is C—R7 or N; with the proviso that at least one of A, B, and D, is N; R5 is hydrogen or C1-6alkyl; R6 is hydrogen or C1-6alkyl; R7 is hydrogen, C1-6alkyl, C1-6alkoxy, or hydroxy; R8 is hydrogen or C1-6alkyl, with the proviso that one of R4 and R8 is hydrogen; R9 is hydrogen or hydroxy; R10 is hydrogen or C1-6alkyl; and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.

Abstract: One aspect of the invention provides a component 112, 165 for a fluid dispenser 110 which defines a dosing chamber 120 for a piston member 114 to stroke in and has an end 160 adapted for engaging a fluid outlet 152 of the fluid dispenser or a seal 154 which overlies the fluid outlet 152 to selectively close and open the fluid outlet 152 or seal 154. Other aspects are disclosed herein.

Abstract: The present invention is directed to pharmaceutical combination products comprising a muscarinic acetylcholine receptor antagonist, fluticasone propionate and salmeterol xinafoate, and to their use in the treatment of inflammatory or respiratory tract diseases.

Abstract: Combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.

Abstract: The present invention is directed to a polypeptide which comprises: (i) an Rv1753c protein sequence; (ii) a variant of an Rv1753c protein sequence; or (iii) an immunogenic fragment of an Rv1753c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis.

Abstract: The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-14, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.

Abstract: This invention relates to methods of making a compound of formula (I) and intermediates for same the compounds of formula (I) being useful for treating cardiovascular and inflammatory diseases such as atherosclerosis.

Abstract: A novel crystalline form of a compound is disclosed.

Abstract: The present invention features compounds of formula (I): and salts thereof, pharmaceutical compositions comprising said compounds, and uses of such compounds in treating or preventing viral infections, such as HCV infections, and diseases associated with such infections.

Abstract: A novel crystalline form of a compound is disclosed.

Abstract: The present invention relates to pharmaceutical formulations comprising an anti-inflammatory glucocorticoid compound of the androstane series and levocabastine, an H1 antagonist/anti-allergic, and also relates to therapeutic uses thereof, particularly for the treatment of inflammatory and allergic conditions, specifically rhinitis.